Marburg virus (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Marburg virus" in English language version.

refsWebsite
Global rank English rank
4th place
4th place
2nd place
2nd place
11th place
8th place
1st place
1st place
18th place
17th place
195th place
302nd place
218th place
212th place
7th place
7th place
102nd place
76th place
5th place
5th place
3rd place
3rd place
2,548th place
1,587th place
low place
low place
719th place
636th place
5,225th place
4,062nd place
5,849th place
7,886th place
621st place
380th place
low place
low place
low place
low place
low place
low place
1,653rd place
1,397th place
28th place
26th place
5,061st place
5,698th place
49th place
47th place
818th place
524th place
97th place
164th place
2,737th place
1,700th place
268th place
215th place
129th place
89th place
low place
low place
low place
6,625th place
115th place
82nd place
447th place
338th place
low place
low place

aljazeera.com

apnews.com

australiagroup.net

barrons.com

biorxiv.org

books.google.com

cbc.ca

cdc.gov

cdc.gov

bt.cdc.gov

china.org.cn

clinicaltrials.gov

cnn.com

doi.org

ebi.ac.uk

fda.gov

genengnews.com

handle.net

hdl.handle.net

harvard.edu

ui.adsabs.harvard.edu

healio.com

iastate.edu

cfsph.iastate.edu

lshtm.ac.uk

researchonline.lshtm.ac.uk

medscape.com

msfaccess.org

  • "MSF's response to CEPI's policy regarding equitable access". Médecins Sans Frontières Access Campaign. September 25, 2018. Archived from the original on March 21, 2021. Retrieved April 10, 2020. In vaccine development, access to know how is important. Knowledge and expertise including but not limited to purification techniques, cell lines, materials, software codes and their transfer of this to alternative manufacturers in the event the awardee discontinues development of a promising vaccine is critically important. The recent example of Merck abandoning the development of rVSV vaccines for Marburg (rVSV-MARV) and for Sudan-Ebola (rVSV-SUDV) is a case in point. Merck continues to retain vital know-how on the rVSV platform as it developed the rVSV vaccine for Zaire-Ebola (rVSV-ZEBOV) with funding support from GAVI. While it has transferred the rights on these vaccines back to Public Health Agency of Canada, there is no mechanism to share know how on the rVSV platform with other vaccine developers who would like to also use rVSV as a vector against other pathogens.

nationalpost.com

nih.gov

pubmed.ncbi.nlm.nih.gov

nytimes.com

reuters.com

selectagents.gov

semanticscholar.org

api.semanticscholar.org

thieme-connect.de

un.org

news.un.org

web.archive.org

who.int

who.int

afro.who.int

worldcat.org

search.worldcat.org

zenodo.org